, Volume 1, Issue 1, pp 27-33

Optimizing adjuvant therapy for colon cancer: Ongoing investigations

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

In 2004, oxaliplatin plus 5-fluorouracil (5FU) and leucovorin (LV) supplanted 5FU/LV as the standard of care for adjuvant therapy of node-positive colon cancer. Data from recently presented phase III clinical trials fail to show a similar benefit for adjuvant irinotecan-5FU/LV over 5FU/LV alone. Current investigations focus on further refining the optimal combination chemotherapy regimen, and incorporating biologic agents into adjuvant therapy of stage II and III colon cancer. In the future, stage-independent prognosticators and markers predictive of chemotherapy response and toxicity may allow for patient-specific selection of more effective and less toxic adjuvant therapy.